SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-030275
Filing Date
2023-02-09
Accepted
2023-02-09 16:59:57
Documents
13
Period of Report
2023-02-07
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d466499d8k.htm   iXBRL 8-K 28384
2 EX-3.1 d466499dex31.htm EX-3.1 114327
  Complete submission text file 0001193125-23-030275.txt   304959

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fbrx-20230207.xsd EX-101.SCH 2859
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbrx-20230207_lab.xml EX-101.LAB 19482
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbrx-20230207_pre.xml EX-101.PRE 12159
7 EXTRACTED XBRL INSTANCE DOCUMENT d466499d8k_htm.xml XML 3666
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

IRS No.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38052 | Film No.: 23607125
SIC: 2834 Pharmaceutical Preparations